Recent Finacing
Recent Raise
Slate Bio is a pre-clinical biotech spinout from UVA developing IL233, a bifunctional IL-2/IL-33 fusion cytokine that augments regulatory and tissue-resident T cells for autoimmune and inflammatory diseases.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
